What Researchers Did
Researchers presented a case report of a patient with an intrathecal baclofen pump referred for hyperbaric oxygen therapy and synthesized manufacturer recommendations for managing implanted neurological devices during HBOT.
What They Found
They found that a 27-year-old woman with an intrathecal baclofen pump could not undergo hyperbaric oxygen therapy due to a lack of safety evidence for her implanted device. Their review of manufacturer guidelines highlighted that neurostimulators should be switched off during HBOT and implanted pumps should be refilled before each treatment.
What This Means for Canadian Patients
Canadian patients with implanted neurological devices considering hyperbaric oxygen therapy should discuss the specific risks and manufacturer guidelines with their healthcare providers. This ensures appropriate device management, such as switching off neurostimulators or refilling pumps, to prevent complications during treatment.
Canadian Relevance
This study is highly relevant to Canada as it addresses a clinical challenge faced by Canadian patients and healthcare providers managing implanted neurological devices in the context of hyperbaric oxygen therapy.
Study Limitations
The study's primary limitation is the reliance on a single case report and a synthesis of manufacturer guidelines, highlighting a broader paucity of direct evidence on device safety in hyperbaric environments.